Shares of HCA Healthcare fell 6.6% in morning trading to $365.07 following the release of preliminary second-quarter 2026 financial results and an immediate downward revision of the company's full-year outlook. Management attributed the guidance adjustments to a worsening payer mix tied to a rise in patients losing coverage via health insurance exchanges.
HCA trimmed its fiscal 2026 earnings-per-share guidance to a range of $28.70 to $30.50 per diluted share, down from a prior range of $29.10 to $31.50. The company also narrowed its revenue forecast for the year to $77.0 billion to $79.5 billion, versus an earlier range of $76.5 billion to $80.0 billion. Adjusted EBITDA guidance was lowered to $15.4 billion to $16.1 billion from the previous $15.55 billion to $16.45 billion range.
On the top line, preliminary second-quarter revenue was approximately $20.23 billion, an increase from $18.61 billion in the year-ago quarter and above the consensus estimate of $19.39 billion. Despite this revenue strength, the trimmed profit outlook dominated market reaction.
The company reported recognizing about $400 million of incremental net benefits from Medicaid Supplemental Payment Programs during the quarter, largely related to Florida. HCA said this reflected the impact of a state-directed payment program approved by the Centers for Medicare and Medicaid Services. Even with that one-time benefit, HCA emphasized a structural shift toward uninsured patients as a material factor weighing on the forward outlook.
Analysts reacted to the guidance changes with price-target reductions. KeyBanc lowered its price target to $475 from $510 while maintaining an Overweight rating. Wells Fargo cut its target to $428 from $436 and retained an Equal Weight rating.
Market context suggested the decline was driven by company-specific news rather than broad market weakness. The S&P 500 rose 0.3% and the Nasdaq gained 0.7% during the same trading period, while HCA shares slid markedly. Commentary from HCA around payer mix dynamics also put pressure on the broader healthcare sector as investors weighed the potential impact on other hospital operators.
HCA noted there have been no significant insider transactions in the past three months, leaving no additional management-sourced signal for investors about the stock's immediate direction.
The combination of a revenue beat and a weaker full-year profitability outlook - rooted in what the company described as a structural shift away from insured patients - emerged as the decisive factor behind the share-price drop. The stock reached an intraday low of $354 following the announcement.
Chief Executive Officer Sam Hazen acknowledged the challenges in remarks accompanying the results, saying the company had "adjusted our guidance to reflect these factors" and expressing confidence in HCA's ability to navigate the changing environment and pursue its long-term strategic plan.
What this means
- HCA posted a notable revenue increase in preliminary Q2 results but reduced full-year earnings and adjusted EBITDA guidance.
- The company attributed the guidance cuts to a worsening payer mix and a growing share of uninsured patients, even after recognizing roughly $400 million in incremental Medicaid-related payments largely tied to Florida.
- Analysts trimmed price targets and the healthcare sector faced pressure as investors digested the implications for hospital operators.